Skip to main content
Premium Trial:

Request an Annual Quote

Gradalis Raises $24M in Series B

Premium

Gradalis announced this week that it has closed a $24 million Series B round of financing.

The money, the firm said, would be used to fund late-stage clinical development of its FANG cancer vaccine, and to ramp up manufacturing to accommodate the therapy's commercial launch. The funding will also be used to advance Gradalis' bi-functional shRNA drug candidates.

The FANG vaccine, which incorporates the shRNA technology, is currently in phase II testing in patients with ovarian cancer, advanced melanoma, and colorectal cancer. Gradalis also has a purely RNAi cancer drug in phase I.

A company official recently told Gene Silencing News that the firm is aiming to expand the use of its technology through partnerships (GSN 10/11/2012).

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.